CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade

BOSSIO, SABRINA N.; ABRATE, CAROLINA; TOSELLO BOARI, JIMENA; RODRIGUEZ, CONSTANZA; CANALE, FERNANDO P.; RAMELLO, MARÍA C.; BRUNOTTO, VALENTINA; RICHER, WILFRID; ROCHA, DARIO; SEDLIK, CHRISTINE; VINCENT-SALOMON, ANNE; BORCOMAN, EDITH; DEL CASTILLO, ANDRES; GRUPPI, ADRIANA; FERNANDEZ, ELMER; ACOSTA RODRÍGUEZ, EVA V.; PIAGGIO, ELIANE; MONTES, CAROLINA L.

OncoImmunology

Taylor and Francis Ltd.

Año: 2023 vol. 12

2162-4011

Conventional CD4+ T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized by the expression of CD39. In several mouse cancer models, we observed that CD39+ Tconv cells accumulated in tumors but were absent in lymphoid organs. Compared to tumor CD39− counterparts, CD39+ Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion. Additionally, CD39+ Tconv cells showed increased production of IFN (Formula presented.), granzyme B, perforin and CD107a expression, but reduced production of TNF. Around 55% of OVA-specific Tconv from B16-OVA tumor-bearing mice, expressed CD39. In vivo CTLA-4 blockade induced the expansion of tumor CD39+ Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39+ Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39+ Tconv cells constituted a heterogeneous cell population with features of exhaustion, high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Our results identify CD39 as a biomarker of Tconv cells, with characteristics of both exhaustion and cytotoxic potential, and indicate CD39+ Tconv cells as players within the immune response against tumors.